KROS
NASDAQKeros Therapeutics Inc.
News · 26 weeks48+67%
2025-12-142026-06-07
Mix2490d
- Insider13(54%)
- SEC Filings7(29%)
- Other3(13%)
- Dividends1(4%)
Latest news
25 items- INSIDERDirector Seth Alpna was granted 7,142 shares, increasing direct ownership by 136% to 12,392 units (SEC Form 4)4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- INSIDERDirector Seth Alpna sold $28,140 worth of shares (2,625 units at $10.72) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 9,767 units (SEC Form 4)4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- INSIDERDirector Gray Mary Ann was granted 7,142 shares, increasing direct ownership by 136% to 12,392 units (SEC Form 4)4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- INSIDERDirector Farzan Nima was granted 7,142 shares, increasing direct ownership by 136% to 12,392 units (SEC Form 4)4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- INSIDERDirector Bienaime Jean Jacques was granted 7,142 shares, increasing direct ownership by 76% to 16,592 units (SEC Form 4)4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- INSIDERDirector Knowles Julius was granted 7,142 shares, increasing direct ownership by 111% to 13,583 units (SEC Form 4)4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- SECKeros Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
- SECKeros Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
- PRKeros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare ConferenceLEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that Keros' President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. Eastern time. A live audio webcast of the fireside chat presentation will be available at h
- INSIDERDirector Bienaime Jean Jacques bought $10,580 worth of shares (1,000 units at $10.58), increasing direct ownership by 12% to 9,450 units (SEC Form 4)4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Keros Therapeutics Inc.SCHEDULE 13G - Keros Therapeutics, Inc. (0001664710) (Subject)
- SECSEC Form 10-Q filed by Keros Therapeutics Inc.10-Q - Keros Therapeutics, Inc. (0001664710) (Filer)
- SECKeros Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
- PRKeros Therapeutics Reports Recent First Quarter 2026 Financial ResultsLEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended March 31, 2026. "Continuing to progress our pipeline remains our top priority, setting the stage for future catalysts and growth opportunities," said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. "In addition, we are excited that our partner
- SECSEC Form DEFA14A filed by Keros Therapeutics Inc.DEFA14A - Keros Therapeutics, Inc. (0001664710) (Filer)
- SECSEC Form DEF 14A filed by Keros Therapeutics Inc.DEF 14A - Keros Therapeutics, Inc. (0001664710) (Filer)
- INSIDERSEC Form 4 filed by Bienaime Jean Jacques4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- INSIDERSEC Form 4 filed by Seehra Jasbir4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- SECSEC Form 144 filed by Keros Therapeutics Inc.144 - Keros Therapeutics, Inc. (0001664710) (Subject)
- INSIDERAmendment: SEC Form 4 filed by Cho Esther4/A - Keros Therapeutics, Inc. (0001664710) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Keros Therapeutics Inc.SCHEDULE 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
- INSIDERSEC Form 4 filed by Keros Therapeutics Inc.4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- INSIDERSEC Form 4 filed by Keros Therapeutics Inc.4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- INSIDERSEC Form 3 filed by Keros Therapeutics Inc.3 - Keros Therapeutics, Inc. (0001664710) (Issuer)
- SECKeros Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
KROS FAQ
7 questionsWhat does Keros Therapeutics Inc. do?
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that...Where does KROS stock trade?
Keros Therapeutics Inc. (KROS) is listed on NASDAQ.What sector and industry is KROS in?
Keros Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Keros Therapeutics Inc. go public?
Keros Therapeutics Inc. (KROS) completed its IPO in 2020.What are analysts saying about KROS?
Keros Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight with a $2600.00 price target on 2025-10-20. Recent price targets range from $1500.00 to $4700.00.What companies are similar to KROS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare KROS side-by-side with any of them on Quantisnow.How can I track KROS on Quantisnow?
Quantisnow aggregates Keros Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KROS to receive live email and push alerts on every new disclosure.